Long Form Content

Longer Form TLDR Biotech content that isn't the usual daily newsletter.

Long Form Content
Long Form ContentLong Form Content
The $4 Million Problem [Guest Post]

The $4 Million Problem [Guest Post]

How a $25M startup is solving gene therapy's $4 million payment problem

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
Building Scalable Biotech Industry Networks - The Biokeiretsu

Building Scalable Biotech Industry Networks - The Biokeiretsu

Biotechnologies Are the Petrochemicals of the Electric Tech Stack

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
Why Biotech is Mortgaging Its Future

Why Biotech is Mortgaging Its Future

Inside the $3.5 Billion Biotech Royalty Financing Surge

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

Hot takes on value creation in biotech

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
TLDR Biotech Big Three Saturday: American Biotech in Flux

TLDR Biotech Big Three Saturday: American Biotech in Flux

Public health dismantling, Chinese asset deals continue, and domestic manufacturing only goes so far

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

Hot takes on current incentive structures

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

The biotech funding model needs a major overhaul

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Long Form ContentLong Form Content
Lowering CAR-T Costs: Paths to more affordable cell therapies

Lowering CAR-T Costs: Paths to more affordable cell therapies

A long form piece by yours truly - originally published on Signals

Anis Fahandej-Sadi
Anis Fahandej-Sadi